Comparative Pharmacology
Head-to-head clinical analysis: LO MINASTRIN FE versus LO OVRAL 28.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LO MINASTRIN FE versus LO OVRAL 28.
LO MINASTRIN FE vs LO/OVRAL-28
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing ethinyl estradiol (estrogen) and norethindrone (progestin). Inhibits ovulation by suppressing gonadotropin release; increases viscosity of cervical mucus, inhibiting sperm penetration; alters endometrial lining, reducing implantation likelihood.
Combination of norgestrel, a progestin, and ethinyl estradiol, an estrogen; suppresses gonadotropin secretion (FSH and LH) primarily via progestational activity, inhibiting ovulation; increases cervical mucus viscosity, impeding sperm penetration; alters endometrial development, reducing implantation likelihood.
1 tablet (1 mg norethindrone acetate/20 mcg ethinyl estradiol/ferrous fumarate 75 mg) orally once daily for 28 consecutive days.
One tablet orally once daily for 28 days. Each tablet contains 0.3 mg norgestrel and 0.03 mg ethinyl estradiol. Active tablets (21 days) followed by placebo tablets (7 days).
None Documented
None Documented
Norethindrone: 8-11 hours; ethinyl estradiol: 12-16 hours. Steady-state achieved after 5-7 days of dosing.
Norgestrel: 20-40 hours; Ethinyl estradiol: 13-27 hours. Steady-state achieved after 3-5 half-lives.
Renal: 40-50% as conjugated metabolites; fecal: 20-30% via biliary excretion; unchanged drug <1%.
Renal (approx. 50% as metabolites, <1% unchanged); biliary/fecal (approx. 50% as metabolites).
Category C
Category C
Combination Oral Contraceptive
Combination Oral Contraceptive